Abstract
The availability of antagonist ligands for somatostatin receptors is very limited, with those that are available often displaying agonist properties or limited receptor subtype selectivity. Hay et al. [Bioorg. Med. Chem. Lett. 11 (2001) 2731] recently described the development of small-molecule somatostatin receptor subtype 2 (sst 2) selective compounds. This study investigates the binding affinity and functional characteristics of two of those antagonists ( 2 and 3) and the agonist compound, from which they were derived ( 1). In radioligand binding studies using the agonist radioligands [ 125I][Tyr 11]SRIF-14 (Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-( 125I-Tyr)-Thr-Ser-Cys]-OH), [ 125I]LTT-SRIF-28 ([Leu 8, dTrp 22, 125I-Tyr 25]SRIF-28; Ser-Ala-Asn-Ser-Asn-Pro-Ala-Leu-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe- dTrp-Lys-Thr-( 125I-Tyr)-Thr-Ser-Cys]-OH), [ 125I]CGP 23996 (c[Lys-Asu-Phe-Phe-Trp-Lys-Thr-( 125I-Tyr)-Thr-Ser]), [ 125I][Tyr 3]octreotide ( dPhe-c[Cys-( 125I-Tyr)- dTrp-Lys-Thr-Cys]-Thr-OH) and [ 125I][Tyr 10]cortistatin-14 (Pro-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-( 125I-Tyr)-Ser-Ser-Cys]-Lys) at human recombinant somatostatin receptors expressed in Chinese hamster lung fibroblast (CCL39) cells and native rat cortex, the compounds bound with high affinity (p K d 6.8–9.7) and selectivity to human sst 2 receptors. Some affinity was also observed for sst 5 labelled by [ 125I][Tyr 3]octreotide and [ 125I]CGP 23996. In functional studies at human sst 2 receptors expressed in Chinese hamster ovary (CHO) cells, both the agonist 1 and the two putative antagonists 2 and 3 concentration dependently inhibited forskolin-stimulated adenylate cyclase and stimulated luciferase reporter gene expression, with similar efficacy to the natural ligand somatotropin release inhibiting factor (SRIF)-14. Compound 1 had similar potency to SRIF-14, which was in the nanomolar range, whereas 2 and 3 were 10–100-fold less potent. The intrinsic activity of 2 and 3 was too high to allow antagonist studies to be carried out. In conclusion, in contrast to previous findings, all three compounds are potent agonists at recombinant human sst 2 receptors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.